Editorial ArticleSimoa Technology aims to transform future Alzheimer's disease detection and treatment
Product NewsQuanterix granted Breakthrough Device designation from U.S. FDA for NfL test for multiple sclerosis
Product NewsQuanterix granted Breakthrough Device designation from U.S. FDA for blood-based pTau-181 assay for Alzheimer’s Disease
Industry NewsQuanterix’ Simoa technology powers largest and most diverse global investigation of plasma neurofilament light’s role in dementia diagnosis
Product NewsQuanterix Launches High-Sensitivity Benchtop Instrument and Assays for Multiplex Biomarker Detection
Product NewsQuanterix Announces Commercial Availability of its Simoa Single Molecule Array Technology
